{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T21:23:14Z","timestamp":1771104194816,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The effect of initiating sacubitril\/valsartan (Sac\/Val) therapy during hospitalization for acute heart failure (AHF) on left ventricular (LV) remodelling remains unclear. This study aimed to assess the impact of Sac\/Val on LV remodelling in patients in whom Sac\/Val was initiated during AHF hospitalization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This study was a sub-analysis of the Program of Angiotensin\u2013Neprilysin Inhibition in Admitted Patients with Worsening Heart Failure (PREMIER) study, which investigated the impact of initiating Sac\/Val during hospitalization for AHF on echocardiographic parameters over an 8-week period, in comparison with the standard renin\u2013angiotensin system inhibitor therapy (control). Among the full analysis set of the PREMIER study, this analysis included 206 patients [mean age, 73 years; 64 females (31.1%)], who had available echocardiographic data. The Sac\/Val group (n = 94) showed significantly improved LV function and morphological parameters at 8 weeks. Compared with the control group (n = 112), preload-dependent parameters improved significantly, including LV end-diastolic volume index [mean, \u22125.1\u2005mL\/m2; 95% confidence interval (CI), \u221210.2 to \u22120.04; P = 0.048] and tricuspid regurgitation peak velocity (mean, \u22120.17\u2005m\/s; 95% CI, \u22120.31 to \u22120.03; P = 0.016). In a subgroup analysis stratified by LV ejection fraction (LVEF), a reverse remodelling effect was primarily observed in patients with an LVEF &amp;lt; 40%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early Sac\/Val initiation after hospitalization for AHF may significantly improve LV function and morphology at 8 weeks, particularly in patients with an LVEF &amp;lt; 40%, supporting its role in LV reverse remodelling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaf061","type":"journal-article","created":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T11:39:28Z","timestamp":1754739568000},"page":"565-573","source":"Crossref","is-referenced-by-count":3,"title":["Impact of early in-hospital initiation of sacubitril\/valsartan on left ventricular reverse remodelling in acute heart failure"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0805-0152","authenticated-orcid":false,"given":"Tomonori","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Hospital , Tokushima 770-8503 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenya","family":"Kusunose","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nephrology, and Neurology, Graduate School of Medicine, University of the Ryukyus , 1076 Kiyuna, Ginowan city, Okinawa 901-2720 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Imai","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Organization for Clinical Medicine Promotion , Tokyo 112-0001 ,","place":["Japan"]},{"name":"Clinical and Translational Research Centre, Kobe University Hospital , Kobe 650-0017 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4585-2437","authenticated-orcid":false,"given":"Yutaka","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kobe City Medical Centre General Hospital , Kobe 650-0047 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiji","family":"Okada","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kobe City Medical Centre General Hospital , Kobe 650-0047 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Kadokami","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saiseikai Futsukaichi Hospital , Chikushino 818-8516 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Kanzaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University , Osaka 569-8686 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisao","family":"Matsuda","sequence":"additional","affiliation":[{"name":"Division of Cardiology, St. Marianna University School of Medicine, Yokohama City Seibu Hospital , Yokohama 241-0811 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Mizukoshi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, St. Marianna University School of Medicine, Yokohama City Seibu Hospital , Yokohama 241-0811 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3464-6016","authenticated-orcid":false,"given":"Keisuke","family":"Kida","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, St. Marianna University School of Medicine , Kawasaki 216-8511 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Matsue","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine , Tokyo 113-8421 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masataka","family":"Sata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokushima University Hospital , Tokushima 770-8503 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-7661","authenticated-orcid":false,"given":"Atsushi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University , 5-1-1 Nabeshima, Saga 849-8501 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2534-0939","authenticated-orcid":false,"given":"Koichi","family":"Node","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Saga University , 5-1-1 Nabeshima, Saga 849-8501 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"2025110321031490500_pvaf061-B1","first-page":"810","article-title":"Contemporary American and European guidelines for heart failure management: JACC: heart failure guideline comparison","volume":"12","author":"Ostrominski","year":"2024","journal-title":"Heart Failure"},{"key":"2025110321031490500_pvaf061-B2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"Authors\/Task Force Members:","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025110321031490500_pvaf061-B3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jjcc.2023.10.009","article-title":"Heart failure management guidelines: new recommendations and implementation","volume":"83","author":"Heidenreich","year":"2024","journal-title":"J Cardiol"},{"key":"2025110321031490500_pvaf061-B4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2025110321031490500_pvaf061-B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025110321031490500_pvaf061-B6","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jacc.2024.01.027","article-title":"Sacubitril\/valsartan in patients hospitalized with decompensated heart failure","volume":"83","author":"Morrow","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2025110321031490500_pvaf061-B7","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1093\/eurheartj\/ehae561","article-title":"In-hospital initiation of angiotensin receptor\u2013neprilysin inhibition in acute heart failure: the PREMIER trial","volume":"45","author":"Tanaka","year":"2024","journal-title":"Eur Heart J"},{"key":"2025110321031490500_pvaf061-B8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jjcc.2023.07.019","article-title":"Implementation of evidence-based heart failure management: regional variations between Japan and the USA","volume":"83","author":"Ichihara","year":"2024","journal-title":"J Cardiol"},{"key":"2025110321031490500_pvaf061-B9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2025110321031490500_pvaf061-B10","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2010.05.011","article-title":"Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach","volume":"56","author":"Kramer","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2025110321031490500_pvaf061-B11","doi-asserted-by":"crossref","first-page":"e008268","DOI":"10.1161\/JAHA.117.008268","article-title":"Combined angiotensin receptor\u2013neprilysin inhibitors improve cardiac and vascular function via increased no bioavailability in heart failure","volume":"7","author":"Trivedi","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2025110321031490500_pvaf061-B12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbrc.2004.07.119","article-title":"Atrial natriuretic peptide inhibits cardiomyocyte hypertrophy through mitogen-activated protein kinase phosphatase-1","volume":"322","author":"Hayashi","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"2025110321031490500_pvaf061-B13","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2741\/4541","article-title":"Mitochondrial DNA, mitochondrial dysfunction, and cardiac manifestations","volume":"22","author":"Lee","year":"2017","journal-title":"Front Biosci (Landmark Ed)"},{"key":"2025110321031490500_pvaf061-B14","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1172\/JCI120849","article-title":"Mitochondrial dysfunction in pathophysiology of heart failure","volume":"128","author":"Zhou","year":"2018","journal-title":"J Clin Invest"},{"key":"2025110321031490500_pvaf061-B15","doi-asserted-by":"crossref","first-page":"11472","DOI":"10.1038\/s41598-023-38694-6","article-title":"Sacubitril\/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model of mitral regurgitation","volume":"13","author":"Tantisuwat","year":"2023","journal-title":"Sci Rep"},{"key":"2025110321031490500_pvaf061-B16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.yjmcc.2017.06.003","article-title":"LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy","volume":"108","author":"Xia","year":"2017","journal-title":"J Mol Cell Cardiol"},{"key":"2025110321031490500_pvaf061-B17","doi-asserted-by":"crossref","first-page":"108954","DOI":"10.1016\/j.biopha.2019.108954","article-title":"The therapeutic impact of entresto on protecting against cardiorenal syndrome-associated renal damage in rats on high protein diet","volume":"116","author":"Yang","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"2025110321031490500_pvaf061-B18","doi-asserted-by":"crossref","first-page":"16542","DOI":"10.1038\/s41598-021-95988-3","article-title":"Cardioprotective effects of early intervention with sacubitril\/valsartan on pressure overloaded rat hearts","volume":"11","author":"Li","year":"2021","journal-title":"Sci Rep"},{"key":"2025110321031490500_pvaf061-B19","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.amjcard.2016.06.040","article-title":"Usefulness of the sum of pulmonary capillary wedge pressure and right atrial pressure as a congestion index that prognosticates heart failure survival (from the evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness trial)","volume":"118","author":"Ma","year":"2016","journal-title":"Am J Cardiol"},{"key":"2025110321031490500_pvaf061-B20","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1002\/ehf2.13355","article-title":"A decrease in tricuspid regurgitation pressure gradient associates with favorable outcome in patients with heart failure","volume":"8","author":"Seko","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2025110321031490500_pvaf061-B21","doi-asserted-by":"crossref","first-page":"e006863","DOI":"10.1161\/CIRCHEARTFAILURE.119.006863","article-title":"Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the CardioMEMS post-approval study","volume":"13","author":"Shavelle","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2025110321031490500_pvaf061-B22","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro\u2013B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"2025110321031490500_pvaf061-B23","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","article-title":"The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study","volume":"38","author":"Schmieder","year":"2017","journal-title":"Eur Heart J"},{"key":"2025110321031490500_pvaf061-B24","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"2025110321031490500_pvaf061-B25","doi-asserted-by":"crossref","first-page":"e012272","DOI":"10.1161\/JAHA.119.012272","article-title":"Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis","volume":"8","author":"Wang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2025110321031490500_pvaf061-B26","doi-asserted-by":"crossref","first-page":"e007901","DOI":"10.1161\/CIRCHEARTFAILURE.120.007901","article-title":"Global differences in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"14","author":"Tromp","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2025110321031490500_pvaf061-B27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cardfail.2022.09.018","article-title":"Epidemiology, pathophysiology, diagnosis, and therapy of heart failure with preserved ejection fraction in Japan","volume":"29","author":"Obokata","year":"2023","journal-title":"J Card Fail"},{"key":"2025110321031490500_pvaf061-B28","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2025110321031490500_pvaf061-B29","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2025110321031490500_pvaf061-B30","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jacc.2022.08.737","article-title":"Dose-response to sacubitril\/valsartan in patients with heart failure and reduced ejection fraction","volume":"80","author":"Mohebi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2025110321031490500_pvaf061-B31","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/ehf2.12305","article-title":"Acute heart failure management in the USA and Japan: overview of practice patterns and review of evidence","volume":"5","author":"Tanaka","year":"2018","journal-title":"ESC Heart Fail"},{"key":"2025110321031490500_pvaf061-B32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cardfail.2021.08.024","article-title":"Hospitalization for heart failure in the United States, UK, Taiwan, and Japan: an international comparison of administrative health records on 413,385 individual patients","volume":"28","author":"Sundaram","year":"2022","journal-title":"J Card Fail"},{"key":"2025110321031490500_pvaf061-B33","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1253\/circj.CJ-23-0350","article-title":"Management and outcomes of acute heart failure hospitalizations in Japan","volume":"88","author":"Kanaoka","year":"2024","journal-title":"Circ J"},{"key":"2025110321031490500_pvaf061-B34","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf061\/64148629\/pvaf061.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/7\/565\/64148629\/pvaf061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/7\/565\/64148629\/pvaf061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T02:03:19Z","timestamp":1762221799000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/7\/565\/8242674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,8,30]]},"published-print":{"date-parts":[[2025,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf061","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,8,30]]}}}